Q-omics provides the consensus-scored GHRLOS profile across patient tissues and cancer cell-line models. GHRLOS expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GHRLOS is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GHRLOS RNA expression shows 16,715 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where GHRLOS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GHRLOS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GHRLOS survival associations across molecular data types. GHRLOS RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GHRLOS RNA expression–survival associations across cancer types. High GHRLOS expression shows unfavorable associations in KIRC, ACC, KICH, LIHC and THCA, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GHRLOS RNA expression.
This table summarizes GHRLOS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GHRLOS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GHRLOS shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in LIHC, UCEC and BLCA. The KIRC box plot shows higher GHRLOS RNA expression in normal versus tumor tissue (log2 FC = −0.528, t-test p < 0.001).
This table shows molecular features associated with GHRLOS in patient tissues and cancer cell lines. In patient samples, GHRLOS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
